Katakami N, Nishimura T, Hidaka Y, Hata A, et al. Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312). Lung Cancer 2023;182:107261.
PMID: 37307753